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     LIST OF ABBREVATIONS   
 ACC                     : American College of Cardiology 
ACE                      : Angiotensin Converting Enzyme 
ACS                           : Acute Coronary syndrome 
AHA                           : American Heart Association  
AMI                           : Acute Myocardial Infarction 
 Apo B                        : Apoprotein B 
Apo(a)                      : Apoprotein (a) 
ARC                      : Atherosclerosis Risk co-efficient 
BMI                       : Body Mass Index 
β-TGF                   : Transforming growth factor -β 
CAD                      : Coronary Artery Disease 
CCS                       : Canadian Cardiovascular Society  
CKMB                   : Creatine Phosphokinase-MB isoenzyme 
CRP                       : C-Reactive Protein 
DM                        : Diabetes mellitus 
GOD-PAP             : Glucose Oxidase-phenol 4-aminophenazone peroxidase 
GUSTO                 : Global Utilization of Streptokinase and Tissue 
Plasminogen Activator in Occluded Arteries 
HDL                      : Heavy Density Lipoprotein 
HGF1                    : Hepatocyte growth-factor  
HMG – CoA          : Hydroxy-methyl Coenzyme A 
IDDM                   : Insulin dependent diabetes mellitus 
IDL                        : Intermediate Density Lipoprotein 
 IL                           : Interleukin 
JVP                       : Jugular Venous Pulse 
 LDH                      : Lactate Dehydrogenase 
 LDL                       : Low Density Lipoprotein 
 LMWH                 : Low Molecular Heparin 
 Lp(a)                     : Lipoprotein (a) 
Lp(a)-C                  : Lipoprotein (a)-Cholesterol 
LTI                         : Lipid tetrad Index 
LV                          : Left Ventricle 
MSP                        : Macrophage-stimulating protein 
NCEP                    : National Cholesterol Education Program 
NIDDM                 : Non-insulin dependent diabetes mellitus 
NPDR                    : Non-Proliferative diabetic retinopathy 
NSTEMI                : Non-ST Elevation Myocardial Infarction 
PAI-I                     : Plasminogen Activator Inhibitor-I R. 
 SD                          : Standard Deviation 
STEMI                   : ST Elevation Myocardial Infarction 
UA                         : Unstable Angina 
UFH                       : Unfractionated Heparin 
VLDL                    : Very Low Density Lipoprotein 
VPBs                      : Ventricular Premature Beats 
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                                            INTRODUCTION 
            Cardiovascular disease has emerged as major health problem worldwide. 
Coronary artery disease (CAD) has a multifactorial origin, including hereditary 
and acquired risk factors which may be the direct cause of the disease or merely 
associated with it. Changes in lipid metabolism play a relevant role in the 
progression of atherosclerosis and the laboratory assessment of lipoproteins is of 
fundamental importance to diagnose and treat this condition. 
         High levels of lipoprotein (a) -Lp (a) are known to be a cardiovascular risk 
factor associated with premature coronary artery disease. Lipoprotein (a) was 
described by Berg in 1963 as a genetic variation of LDL. Lp(a) presents a lipid 
composition which is similar to the composition of LDL, but with different 
protein content, since it presents the apolipoprotein (a) or Apo(a) linked to 
apolipoprotein B by disulfide bridges. The serum levels of Lp (a) and the 
molecular mass of Apo (a) vary greatly between people and are genetically 
determined. Lp (a) has no function in the transport of lipids and therefore its 
absence in the serum does not cause metabolic disruptions. 
        Apo (a) is highly homologous to plasminogen, the inactive precursor of 
plasmin - the protein that breaks up the fibrin produced during the coagulation 
process - due to the varied number of repetitions of amino acid sequences which 
are homologous to the kringle region of plasminogen. This structure allows the 
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binding of Lp(a) to fibrin and to the proteins of the cell surface of endothelial 
cells and monocyte, as well as the competitive inhibition of tissue plasminogen 
activator (t-PA), reducing the generation of plasmin and fibrinolysis. These 
characteristics provide Lp (a) with pro-atherogenic properties, in that high levels 
of this lipoprotein are associated with early CAD risk, cerebrovascular disease 
and restenosis of coronary lesions. Some authors consider Lp (a) an independent 
risk factor for coronary and brain artery atherosclerosis in Caucasian, Chinese, 
African and Indian individual. 
  Newer cardiovascular risk factors are of great importance in Indians, where 
more than 60 per cent of CAD remains unexplained by conventional risk 
factors. Comparative studies on newer risk factors illustrated that Indians have 
high levels of lipoprotein (a), CRP, homocysteine levels. Lipoprotein (a) level is 
consistently elevated in Indians compared to other groups. 
 Type 2 diabetes mellitus (DM) is associated with significant cardiac morbidity 
and mortality with a more than threefold increased risk of coronary artery 
disease (CAD). However, this increased cardiovascular risk is only partially 
explained by conventional risk factors, including hypertension, lipid 
abnormalities, central obesity, and glucose intolerance.  Lipoprotein (a) (Lp(a))  
is an independent risk factor for CAD. There is controversy in findings of 
studies regarding relation between serum Lp (a) level and diabetes. Some 
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reported increased level of serum Lp (a) in uncontrolled diabetic patients, while 
some others did not.  However, it is shown that cholesterol [LDL, IDL, VLDL, 
Lp (a)] is a predictive factor for CHD in diabetic men and women. Therefore, 
this study was designed to compare the serum Lp (a) level in patients with type2 
diabetes and non-diabetic individuals. 
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AIM AND OBJECTIVES: 
 
 
 
 
 
 
 
 To compare the level of lipoprotein (a) level in type 2 diabetics 
and non diabetics in association with acute coronary syndrome. 
 To assess whether lipoprotein (a) level is increased in type2 
diabetics when compared to non diabetics 
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                                    REVIEWOF LITERATURE 
 
                             Lipoprotein (a) is LDL like particle which differ from LDL by 
specific apolipoprotein (a) which is covalently bound to apolipoprotein B by 
disulphide group. It  was discovered by Berg in 1963. Lipoprotein (a) helps in 
transport of lipids and the gene locus for the Lp(a) is chromosome 6q(26-27). 
Most of the studies revealed that Lp(a) is one of the important risk factor for 
atherosclerotic diseases like stroke and coronary artery disease.  
STRUCTURE  
 
6 
 
Lp(a) is metabolically distinct from LDL. The Apo(a), have multiple repeated 
plasminogen kringle (k) domains. This makes the Lp(a) isoform  which 
determines its heterogenecity . 
Lipoprotein(a) depends on its isoform of Apo(a) for its metabolic and 
physiochemical properties. 
 
Lipoprotein (a)  
The size of the Apo (a) depends on kringle IV repeats in it. The variable Apo (a) 
sizes are called as Apo (a) isoform and there is inverse relation between the 
Lp(a) plasma concentration and the size of Lp(a). 
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Apo (a) is produced by the hepatocyes and at the outer surface of hepatocytes 
Apo(a) combines with Apo(B) of LDL particles to form Lp(a). The plasma half 
life of Lp(a) in circulation is 3 to 4 days. The large and small LDL particles 
differ in the cholesterol content of lipid core. The lipid core of the LDL particle 
is surrounded by Apo-B 100 and unesterified 
  
Cholesterol phospholipids.  The large and small Lp(a) proteins, is due to the 
repeated sequence of kringle domain in apolipoprotein(a). 
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        Apo(a) has different type of kringle IV followed by kringle V and a non  
functional protease domain and the Apo(a) length depends on number of repeats 
of kringle IV type  2, which is genetically determined. 
METABOLISM 
      Apo (a) is predominantly synthesized in the hepatocytes of the liver. The 
Apo (a) has high affinity to combine with Apo-B of the LDL receptor at the 
outer surface of hepatocytes. The Apo(a) is covalently bound to Apo-B 100 via 
a disulfide bridge to the free cysteine group in k IV of Apo(a). 
     The binding between apolipoprotein (a) and the Apo-B makes the Lp(a) to 
have low affinity to uptake by LDL receptor.  
     The catabolism of the Lp(a) is to a large extent unknown. Initially, it was 
thought that Lp(a), like other lipoproteins, was degraded by LDL receptor. But 
in many experiments its shown that, Lp(a) has low affinity to the LDL receptor. 
The plasma half life of Lp(a) is higher when compared to LDL gives the 
conclusion that LDL receptor practically has no function in the metabolism of 
Lp(a).  
     The Apo(a) is separated from Apo-B in the blood and undergoes 
fragmentation in to degradation products of different molecular weight by the 
metalloproteinases. These are removed from circulation by different tissues and 
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organs and small amount of Apo(a) is excreted via urine. The other receptors 
that are associated with Lp(a) metabolism are galactose specific 
asialoglycoprotein receptor and the protein- megalin, the VLDL receptor.  
The levels of Lp(a) are elevated in following conditions 
 Coronary artery disease 
 Stroke 
 Diabetes mellitus  
 Chronic renal failure  
 Nephrotic syndrome  
 Severe hypothyroidism  
 Familial hypercholesterolemia 
 Patients receiving cyclosporine   
 Oestrogen depletion  
    The levels of lipoprotein (a) level is low in chronic alcoholics, chronic liver 
disease and malnutrition.  
Lp(a) in wound healing: 
Normally the function of Lp(a) is transport of cholesterol to the site of the lesion 
and also causes vascular smooth muscle cell migration and subsequently 
proliferation. So Lp(a) is the necessary molecule for supply of cholesterol for   
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tissues which need cholesterol for tissue repair. Hence Lp(a) plasma 
concentration is increased as a acute phase reactant. This normal evolutionary 
advantage has been transferred in to pathologic mechanism for premature 
atherogenesis.  
 
                                        Lipoprotein (a) role in tissue repair 
Lipoprotein (a) has Interleukin-6 responsive elements. So the Lp(a) is recognised 
by the interleukin receptors of macrophages, fibroblasts, platelets and endothelial 
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cells due to the presence of Apo(a). From the activated neutrophils, defencin is 
released which causes binding of Lipoprotein(a)  to endothelial and the Lp(a) 
binds to vascular walls by lysing binding sites (LBS) of Apo(a) moiety. Lp(a) 
promote cell repair by transport of cholesterol. The hypothesis was supported by 
Yano and colleagues by markedly positive staining for Lipoprotein (a) along the 
surface of the fibrous cap and in endothelial cells in extra cellular space of small 
vessels during wound healing.   
Lp(a) in angiogenesis 
    Lp(a) has the structure similar to that of plasminogen. Lp(a) has also anti 
angiogenesis effect. 
    Angiogenesis is defined as new vessel formation which starts with the 
remodelling of matrix proteins and matrix metalloproteinases as inactive 
zymogens. These should be activated by proteases such as plasminogen. The 
Apo(a) in the Lp(a) is structurally similar to plasminogen and thereby 
competitively inhibits the plasminogen. It indicates that Lp(a) has an anti 
angiogenesis effect.  
  In experiments, it's shown that Apo (a) leads to an inhibition of angiogenesis 
dependant tumour growth in the colon. As a result, the plasma concentration of 
Lipoprotein (a) is found to be higher in tumour patients than the healthy 
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individuals. The anti angiogenesis effect of Lp (a) is only little known and so it 
needs further investigation to prove that Lp(a) has a protective effect against 
tumour formation. 
Lipoprotein (a) in atherosclerosis: 
     The Lp (a) particles undergoes oxidation results in forming oxidized Lp(a) 
which has high affinity for monocyte chemo attractant and leads to the 
recruitment of mononuclear phagocytes to the vascular walls results in 
cholesterol accumulation and foam cell formation leading to atherogenesis. 
       In diabetic patients patient, as a result of hyperglycemia there will be 
increased production of non enzymatic glycation end products. These products 
combine with lipoproteins undergoes oxidation which contributes to the 
premature atherogenesis.  
Role of Lp(a) in thrombosis:  
Normally the plasminogen is activated by comprising fibrin and tissue 
plasminogen activator. There by it encourages thrombolysis and activates 
TGFβ. The athero protective effect of TGFβ is by inhibition of smooth muscle 
cell migration and proliferation an also it causes inhibition of endothelial cell 
migration. 
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As in elevated level of lipoprotein (a), the activation of plasminogen is impaired 
by increased expression of plasminogen activator inhibitor-1 and SERPINIA 
causes inhibition of tissue plasminogen activator. 
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Lp(a) also enhances the activation of alpha2macroglobulin,a plasmin inhibitor 
there by promotes a prothrombotic effects. 
Lp(a) in coronary artery disease: 
        In several studies ,they showed a direct relationship between increased 
Lp(a) levels and coronary artery disease. In asian population ,many studies 
revealed that Lp(a) is one of the independent risk factors for CAD compared to 
other populations .other conventional risk factors like cigarette smoking 
,hypertension ,and hypercholesterolemia are affected by life style modification 
But the Lp(a) levels  and the insulin resistance syndrome are not affected by 
drugs and life style modification.  
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Mechanism linking lipoprotein (a) to thrombosis and atherosclerosis: 
lipoprotein(a) (Lp[a]) causes  thrombosis and atherosclerosis. 
.  
 Venn diagram depicts a series of factors that potentially contribute to venous 
thrombosis (left side) and athero thrombosis (right side). A subset of these 
factors that are influenced by Lp(a) is contained in the filled circles; note that all 
the factors potentially contributing to venous thrombosis that are influenced by 
Lp(a) are in common with atherothrombosis (centre). Factors that contribute 
uniquely to venous thrombosis or atherosclerosis, and are not influenced by 
Lp(a), are contained in the open circles. EC (endothelial cell) ECM, 
extracellular matrix; HDL- high-density lipoprotein; LDL- low-density 
lipoprotein; PAI-1, plasminogen activator inhibitor type 1; PL, phospholipids; 
SMC, smooth muscle cell; TFPI, tissue factor pathway inhibitor activity. 
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Cellular and molecular mechanism of Lp(a): 
1. AGGREGATION OF PLATELETS: 
       When there is damage to blood vessels, when exposed to collagen the 
platelets get activated. There will be secretion of dense granules which causes 
aggregation of other platelets occurs by binding of fibrinogen to integrin on the 
surface of platelets there by clot formation is intiated. 
Lp(a) promote activation of platelets via thrombin receptor activated 
hexapeptide and arachidonic acid. it has been demonstrated in many studies , 
that Lp(a) has inhibitory effect at low concentration of collagen. However the 
inhibitory effect was not observed in high concentration of collagen. 
2. Tissue factor pathway: 
                Lp(a) causes increased production tissue factor (TF) which is one of 
the important part of  coagulation system which leads to activation of thrombin 
increased production of TF by Lipoprotein(a) is done by activation of integrin 
and nuclear factor kappa B signalling cascade .Lp(a) also favour thrombosis by 
binding to  tissue factor and thereby it inhibits the tissue factor pathway 
inhibitor. 
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3. Impairment of plasminogen activation: 
 The formation of plasmin is inhibited by lipoprotein (a) by competitively 
inhibiting the plasminogen activator such as plasminogen and fibrin. It promotes 
thrombosis by preventing clot lysis by inhibiting plasmin. 
Lp(a) also inhibit the secretion of tissue plasminogen activator from endothelial 
cells. Lipoprotein(a) also increases the expression of PAI-1 (plasminogen 
activator inhibitor-1)in coronary artery and protein kinase c dependent 
mechanism. 
   Lp(a) also enhances production of alpha 2 macroglobulin which is a plasmin 
inhibitor and serine proteinase inhibitor A1 -tissue plasminogen activator 
inhibitor. Resulting in Lp(a) promotes thrombosis by inhibiting the association 
of plasminogen, fibrin and tissue plasminogen activator which impairs 
fibrinolysis. 
4. Inhibition of TGFβ activation: 
      Plasmin which normally activates transforming growth factor β in clot lysis 
pathway causes inhibition of smooth muscle cell migration and proliferation 
which gives protection against atherosclerosis. 
Lp(a) by inhibiting plasminogen activation  also inhibits the activation of TGFβ. 
So the smooth muscle cell migration and proliferation within the vessel wall 
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occurs favouring atherosclerosis. Lp(a) also reduces the bioavailability of TGFβ 
favours atherosclerosis. 
5. Inflammatory cell recruitment and activation; 
   Lp(a) levels are increased as an acute phase reactants ,as in inflammatory 
process.  
 
 
Interleukin 6 through binding to Apo(a) of Lp(a) at multiple sites promotes 
production of Lp(a) as an acute phase reactants. Lipoprotein(a) has high affinity 
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to incoporate and take oxidised phospholipids which promote secretion of 
cytokines results in interaction of inflammatory cells to the injury site.  
6. Transport of oxidised phospholipids: 
Lp(a)  binds to oxidised phospholipids preferentially which lead to their 
deposition within the vessel wall results in promoting atherogenesis. 
7. Chemoattraction; 
        Lp(a) can induce chemotaxis and attract monocytes. Smaller Lp(a) 
isoforms are more potent monocyte chemo attractant which associated with 
greater cardiovascular risk. Lp(a) activates protein kinase c and increase 
intracellular levels of cyclic GMP resulting in chemokinesis. Lp(a) also 
promotes their migration of monocytes through the endothelium. 
8. Adhesion of inflammatory cells to endothelium; 
Lp(a) promotes adhesion of monocyte by binding through integrin. Lp(a) also 
increases the production of vascular cell adhesion molecule(VCAM-1) and E-
selctin. 
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9. Vascular remodelling: 
           Lp(a) has its effect on vascular remodelling. It is done by activating 
multiple signalling pathways within the smooth muscle cells and endothelial cell 
which depends upon the oxidised state of lipoprotein(a) molecule. 
 
The proliferation of smoth muscle cells is induced by inhibition of TGFB 
activation by lipoprotein(a).A common intacellular signalling pathway linked to 
proliferation of extracellular signal related kinase which result in smooth muscle 
cell proliferation. 
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Lp(a) also promotes smooth muscle cell proliferation within the vessel wall by 
increasing the expression of PDGF(platelet derived growth factor).oxidised 
Lp(a) is more potent mediatpr of vascular dysfunction than native Lp(a). 
LIPOPROTEIN(a) in VARIOUS POPULATION: 
various new cardiovascular riskfactors that are emerged in asian indians are  
 Lipoprotein(a) 
 C-reactive protein 
 Plasminogen activator inhibitor 
 Homocysteine levels 
In which Lp(a) levels are consistently elevated in asian indians compared to 
other ethnic groups. Lp(a) is one of the most important independent risk factor 
for coronary artery disease. In South Indian populations also most of the studies 
revealed that Lp(a) levels are increased in those groups. But when compared to 
Asian and European population the plasma concentration of lipoprotein(a) 
levels are two to three fold high in African population. 
It  projected to rise to 80 million in the year 2030. 
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DIABETES MELLITUS: 
                                        Diabetes mellitus is a metabolic cum vascular 
syndrome of multiple etiologies characterised by chronic hyperglycemia with 
disturbances of carbohydrate, fat and protein metabolism resulting in defects in 
insulin secretion, insulin action or both leading to change in both small blood 
vessels(microangiopathy) and large blood vessels (macroangiopathy). This 
disorder is frequently associated with long term damage, which can lead to 
failure or malfunction of organs like kidneys, eyes, ,heart and blood vessels. 
Diabetes is the single most important metabolic disease which can affect nearly 
every organ in the body and is therfore widely  recognized as one of the leading 
causes of death and disability worldwide. 
India has the dubious distinction of being called THE DIABETIC CAPITAL 
OF THE WORLD as it is presently estimated to have over 32 million 
individuals affected by this deadly disease. 
TYPES OF DIABETES: 
1.Type 1 diabetes 
          Immune mediated 
          Idiopathic 
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2.Type 2 diabetes 
3.Other specific types; 
         a.genetic defects of beta cell function-MODY 
          b.genetic defects in insulin action 
          c.disease of exocrine pancrease 
          d.endocrinopathies 
          e.drug or chemical induced diabetes 
          f.infection 
          g.uncommon forms of immune mediated diabetes 
          h.genetic syndromes sometimes associated with diabetes mellitus 
4.Gestational diabetes mellitus 
 
 
 The following are the characteristics of type 2 diabetes:  
 
1.  Associated with defects in both insulin secretion and action 
 
 2. Occurs at any age, usually diagnosed > 30 yrs 
 
3. Age of clinical presentation may be decreasing in some ethnic groups 
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4. Although ~80% of patients are obese or have a history of obesity at the  
 
time of diagnosis, it can also occur in non-obese, especially the elderly 
 
5. Type 2 diabetic patients may not present with the classic symptoms of  
 
diabetes such as polyuria, polydypsia, polyphagia and weight loss.   
 
6. Type  2  diabetic  patients  are  not  prone  for  ketoacidosis  except  during 
severe stress, such as infections, trauma, medications or surgery. 
7. Type 2  d i a b e t i c  p a t i e n t s  f r e q u e n t l y  p r e s e n t  w i t h  
mi c r o v a s c u l a r  a n d  macrovascular chronic complications of diabetes. 
Indications for diabetes screening in asymptomatic adults includes the 
following 
A. Sustained blood pressure >135/80 mm Hg 
B. Overweight and 1 or more other risk factors for diabetes (e.g., first-degree 
relative with diabetes, BP >140/90 mm Hg, and HDL < 35 mg/dl and/or 
triglyceride level >250 mg/dl) 
C.ADA recommends screening at age 45 years in the absence of the above 
criteria  
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         Lp(a) is one of the non modifiable risk factors since it is genetically 
determined. 
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DIAGNOSIS OF TYPE 2 DIABETES MELLITUS: 
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Metabolic abnormalities in Type 2 diabetes mellitus: 
    The prominent feature of type2 DM is insulin resistance. Insulin resistance is 
defined as the decreased ability of insulin to act effectively on target tissues like 
muscle, fat and liver. 
Insulin resistance results in  
1. Impairment of glucose utilization by insulin sensitive tissues. 
2. Increased production of glucose by the liver. 
Both effect will contribute to the hyperglycemia. 
The obesity associated with type 2 DM is considered to be the part of the 
pathogenic process in developing insulin resistance. In obesity,  due to increased 
adipocyte mass leads to increased levels of circulating free fatty acids and 
adipokines. They may cause insulin resistance in skeletal muscle and liver. 
Impaired insulin secretion: 
        Initially in type 2DM, insulin secretion is increased to compensate for 
insulin resistance to maintain normal glucose.But in long standing type 2 
diabetes, beta cell mass is decreased resulting in insulin deficiency. 
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Insulin resistance syndrome: 
Insulin resistance syndrome is defined as collection of metabolic derangements 
that include hypertension, insulin resisteance, dyslipidemia, type 2 diabetes or 
IGF/IFG, central or visceral obesity and accelerated cardiovascular disease. 
TYPE A; 
-it affects young women 
-have an undefined defect in insulin signalling pathway. 
-they have feature of hyper androgenism, hyper insulinemia and obesity 
TYPE B: 
-affect middle age womem 
-have autoantibodies directed against insulin receptor. 
-features of hyper androgenism, hyperinsulinemia and auto immune disorders. 
ACUTE COMPLICATION OF DM: 
1. Diabetic ketoacidosis 
2. Hyperglycemic hyperosmolar state 
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CHRONIC COMPLICATION OF DM: 
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MECHANISM OF COMPLICATION: 
       The important etiological factor in diabetes is chronic hyperglycemia which 
causes the complications of DM 
Theories that postulated for chronic complication of diabetes mellitus  
1.Increased intracellular glucose 
 
  increased formation of advanced glycosylation end products 
 
which will accelerate atherosclerosis, reduce nitric oxide synthesis, alter extra 
cellular matrix composition and structure, induce endothelial dysfunction and 
promote glomerular dysfunction. 
2.Chronic hyperglycemia 
 
increase glucose metabolism via sorbitol pathway results in increases sorbital 
concentration 
increases cellular osmolality and generate reactive oxygen species. 
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3. Hyperglycemia causes increased formation of diacylglycerol leading to 
activation of protein kinase c  
 
which alters the transcription of genes for fibronectin, typeIV collagen, extra 
cellular matrix protein in endothelial cells and neurons. 
4. Chronic hyperglycemia increases hexosamine pathway and there by increased 
production of fructose  phosphate which alters glycosylationof proteins,TGF 
BETA or PAI-1. 
DIABETIC RETINOPATHY: 
Diabetic retinopathy is a common complication of diabetes posing a serious 
threat to vision in diabetic patients. Diabetic retinopathy is the affection of the 
small vessels on the retina due to prolonged uncontrolled hyperglycemia leading 
to apperance of microaneurysms, hemorrhages, exudates and new vessel 
formation in the retina. 
Classification of Diabetic retinopathy: 
1. Non proliferative diabetic retinopathy 
2. Proliferative diabetic retinopathy 
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PATHOGENESIS OF DIABETIC RETINOPATHY: 
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Management of diabetic retinopathy: 
1.               Good glycemic control 
2.           Medical management using aldose reductase inhibitors are being 
investigated in the treatment of diabetic retinopathy. This is based on the 
concept that glucose freely enters the cells lining the vessel wall, where it is 
converted to sorbitol by aldose reductase. Sorbitol in the cells exerts a harmful 
osmotic effect. Sorbinil, one of the aldose reductase inhibitors has shown 
promising prospects but the final result is still awaited. 
3.       Calcium dobesilate and methycobal are also found to be used in 
retinopathy. ACE inhibitor also retards the progress of retinopathy. PKC 
inhibitors are promising drugs in the prevention of progression of retinopathy. 
4.            PHOTOCOAGULATION 
                 In situations where the vision is being seriously threatened, 
photocoagulation is advocated. Maximum benefit is derived when the treatment 
is given early when the visual acuity is reasonably good. Satisfactory results are 
obtained in macular edema, focal leakage and hard exudates. But when there is 
ischemic edema, the results are less satisfactory. 
                In proliferative retinopathy also, significant benefit can be derived by 
the judicious use of photocoagulation. Argon laser therapy is the method of 
34 
 
choice under these conditions.The principle behind photocoagulation is that the 
destruction of ischemic retina prevents the release of angiogenic factor. 
5.          VITRECTOMY 
              Vitrectomy is the treatment of in vitreous hemorrhage, fractional 
detachment and in the removal of epiretinal membranes. A visual acuity of 
atleast 5/200 is necessary pre operatively to achieve a favourable outcome. 
Vitreous hemorrhage can occur during the course of vitrectomy surgery but 
usually clears slowly over a period of weeks. 
DIABETIC NEPHROPATHY: 
                       Diabetic nephropathy is one of the leading causes of chronic renal 
failure and end stage renal disease. This is due to the increasing prevalence of 
type 2 diabetes, longer life span of diabetic patients and improved therapeutic 
options. In the case of type 2 diabete, it has slow progression and about 20 
percent reach ESRD as most of the patients die due to coronary artery disease. It 
is the most important cause of morbitidy and mortality in type1 diabetic 
patients, as 35% reach ESRD 
   Diabetic nephroopathy is clinically defined as the presence of persistent 
proteinuria of more than 500 mg/day in a diabetic patient with concomitant 
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evidence of diabetic retinopathy and hypertension, in the absence of other 
kidney or renal disease. 
    Diabetic patients are 17 times more prone to develop nephropathy than the 
general population. The peak onset of DN in type 1 diabetes is between 10-15 
years after onset of disease. 
Pathological changes in diabetic nephropathy  
The distinctive lesions seen are 
1. Nodular inter capillary glomerulosclerosis(kimmelsteil wilson lesion) which 
is pathognomonic of diabetes mellitus 
2. Diffuse inter capillary glomerulosclerosis which can lead to decrease in blood 
flow and thus reduction in GFR. 
3. Capsular drop seen between the layers of Bowman's capsule 
4. Fibrous cap seen in between the endothelial cell layer and the basement 
membrane 
5. Arteriolar hyalinosis. 
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RISK FACTORS FOR DIABETIC NEPHROPATHY 
 1. Hypertension 
2. Hyperglycemia 
3. Microalbuminuria 
4. Duration of diabetes 
5. Family history 
6. Ethnicity 
7. Male gender 
8. Cigarette smoking 
9. Hyperlipidemia 
Clinical features of diabetic nephropathy 
1. Proteinuria is the hallmark 
2. Fluid retention 
3. Diabetic hypertension 
4. Retinopathy 
5. Neuropathy 
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6. Arterial disease 
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               STAGES OF DIABETIC NEPHROPATHY 
DIABETIC NEPHROPATHY AND PREGNANCY: 
   The presence of microalbuminuria and proteinuria indicates poor prognosis 
for both mother and fetus during pregnancy as they are strong predictors of 
preeclamsia. Treatment with ACE inhibitors and tight glycemic control for at 
least 3 months prior to pregnancy reduces the risk. During pregnancy methyl 
dopa or calcium channel blockers can be given for control of blood pressure as 
ACEI are contraindicated. 
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Primary prevention of diabetic nephropathy 
Primary prevention involves intervention before stage1-hyperfiltration 
hyperperfusion develops 
1. Early diagnosis of diabete mellitus and strict control of blood glucose from 
the very begining. 
2. Control of hypertension. 
3. Lipid control. 
4. Dietary protein of acceptable quality 
5. Identification of high risk group such as those with family history of 
hypertension. 
Management of diabetic nephropathy: 
1. Control of hyperglycemia 
2. Dietary protein restriction  
                 Low protein diet (40g/day) in overt nephropathy retards the 
progression of renal disease. Proteins from vegetable source are preferable. 
3. Control of hypertension 
40 
 
                 Normalizing the blood pressure at every stage of progressive diabetic 
renal disease is stressed as an important component of the therapeutic program. 
Blood pressure should be reduced to a standing BP of 120/70 to 130/80 mm hg. 
In normoalbuminuric patients, a reduction in hyperfiltration is observed by the 
use of ACE inhibitors. ACE  inhibitors are more benefitial in the stageof 
incipient nephropathy. In some type 2 diabete with microalbiminuria, ACE 
inhibitors may increase serum creatinine if the patients happens to have renal 
artery stenosis or hyperkalemia. Hence serum creatinine and electrolytes should 
me measured after intiation of therapy, whenever the dose is changed or atleast 
3to 4 times in a year. Raised arterial blood pressureaffects the renal damage in 
diabetics in a complex way. Intrarenal hypertension is the pathogenetic factor in 
the progressionof renal disease. Effective normalization of these factors by ACE 
inhibitors not only reduce the proteinuria but also postpones the ESRD. 
      Other antihypertensive drugs that are effective are non-dihydropyridine, 
calcium blockers and angiotensin II receptor blockers. Nifidipine and 
amlodipine are also useful in patients who cannot tolerate ACE inhibitors. 
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Control of urinary infections: 
       Urinary infections are one of the principal causes for the worsening of renal 
function in an otherwise stable uraemic diabetic and require to be sought for 
and energetically treated with appropriate antibiotics. Because of renal 
insufficiency (creatinine clearance less than 40 ml/min) potentially toxic drugs 
excreted by the kidneys, such as amino glycoside antibiotics must be 
administered in reduced dosage  and monitored. Contrast agents induced renal 
failure occurs with increasing frequency in those with a creatinine clearance of 
less than 25ml/min and hence such agents are better avoided. 
Diuretics 
  As the renal reserve declines to about 25% of normal value, chlorthiazide and 
hydrochlorthiazide becomes ineffective and must be replaced by a loop diuretic 
such as furosemide. As the creatinine clearance falls to 10-20 ml/min, as high as 
480 mg of furosemide daily may be required to effect diuresis.     
DIABETIC NEUROPATHY: 
   Diabetic neuropathy is a heterogenous condition that encompasses a wide 
range of peripheral nerve dysfunction and whose development might be 
attributed to diabetes per se or to factors associated in the disease. It is the most 
common and most troublesome of all diabetic complications. 
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Diabetic neuropathy is defined as the presence of symptoms and signs of 
peripheral nerve dysfunction in people with diabetes after exclusion of other 
causes the neuropathic dysfunction. It is manifested in the somatic and 
autonomic nervous system. 
CLASSIFICATION OF DIABETIC NEUROPATHY: 
 
 
 
PATHOGENESIS OF DIABETIC NEUROPATHY: 
                                   Peripheral nerves are composed of several different types 
of nerve fibers, each with their own function. The large myelinated A-α fibers 
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conduct rapidly and subserve motor power, proprioception and coordination. 
The thinner yet myelinated A-δ fibers subserve cold  thermal detection and deep 
seated pain.The thin unmyelinated C fibers are responsible for warm detection 
threshold, heat pain and part of touch sensation nerve supply to the skin. 
                        Axonal degeneration and segmental demyelination have been 
documented to be the histological hallmark of diabetic neuropathy. Intraneural 
vascular thrombi have also been observed. Both large fibers(mediating motor 
axons,proprioception and afferents for the reflex arc) and small fibers( 
mediating pain, temperature and autonomic outflow) are involved in diabetic 
neuropathy. 
                       The axonal changes precede the loss of myelin, believed to be due 
to secondary dysfunction of schwann cells. Axonal sprouts have a large number 
of alpha receptors. Besides conducting nerve impulses they have the capacity to 
generate impulses and thus serve as pacemakers. Thus the peripheral nerve in 
diabetic neuropathy with a decreased axon and axonal sprouting manifests 
clinically as loss of sensation or of spontaneous pains due to diseased axon ,as 
well as occurrence of spontaneous pains(due to axonal sprouting)in the area 
supplied by the affected nerve. Patients experiences pain spontaneously but not 
when tested subjective not objective (painless painful leg). 
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Stages of neuropathy                                            characteristics 
1. No neuropathy                                               -   no symptoms and signs 
2. Clinical neuropathy chronic painful               -     burning, shooting, stabbing                    
pain, and pin and needles; increased at night, absent sensation to several 
modalities, reduced/absent reflexes. 
3. Acute painful - severe symptoms as above(hyperesthesia common), 
4. Painless with complete/partial sensory loss   -numbness/deadness of feet or 
no symptoms, painless injury, reduced/absent sensation, reduced thermal 
sensation, absent reflexes.  
5. Late complications amputation  -foot lesion, neuropathic deformity. 
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PATHOPHYSIOLOGICAL MECHANISM OF DIABETIC 
NEUROPATHY 
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AUTONOMICNEUROPATHY: 
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Treatment of painful neuropathy: 
      Many drugs have been tried to offer relief from painful neuropathic 
symptoms. These include simple analgesics, non steroidal anti inflammatory 
drugs, tricyclic anti depressants, and anti convulsants. 
 
 
         Treatment algorithm for the patients with diabetic neuropathy. 
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Dyslipidemia in diabetes 
Diabetus mellitus is associated with abnormalities in lipoprotein and lipid levels 
referred as dyslipidemia which is more common in type 2 diabetes than the   
type-1 diabetes.  
Normally, insulin is necessary for lipid metabolism and apolipoprotein 
production in liver and peripheral tissue such as endothelial cells, skeletal 
muscle, adipocytes and fibrocytes. Insulin by enhancing lipoprotein lipase 
activity helps in lipolytic pathway results in increased clearance of 
chylomicrons and very low density lipoproteins.  
Lipoprotein abnormalities seen in diabetes mellitus 
Type-1 diabetes mellitus 
In type-1 diabetes mellitus patients, under good glycemic control there is no 
abnormalities in lipids. When there is poor glycemic control there is increased 
oxidation of triglycerides and low density lipoprotein. But when type-1 diabetes 
mellitus patient develop diabetic nephropathy, there will be high LDL 
cholesterol and intermediate HDL.    
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Type-2 diabetes mellitus 
In type-2 diabetes mellitus patients when there is good glycemic control also 
patients have high triglycerides and intermediate HDL cholesterol and there will 
be increased small dense LDL particles which is more atherogenic.  
In type-2 diabetes mellitus patients with poor glycemic control, there will be 
worsening of hyper triglyceridemia and high lipoprotein(a) levels. When they 
develop diabetic nephropathy, there will be high TGL, high Lp(a) and 
intermediate HDL. 
Dyslipedemia plays an important role in diabetic complications and there is 
pronounced acceleration of atherosclerosis. In hyperglycaemia there is increased 
production of advanced glycation products which gives rise to reactive oxygen 
species. Normally endothelial cells secrete biologically active substances such 
as nitric oxide from nitrogen terminal of L-arginine by means of oxidation in the 
presence of endothelial nitric oxide synthase. Nitric oxide maintain vascular 
homeostasis, ensuring  adequate blood flow and nutrient delivery while 
preventing thrombosis and leukocyte diapedesis, smooth muscle cell migration. 
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1. Hyperglycemia causes nitric oxide activity there by it produces increased 
activity of pro inflammatory chemokines and cytokines. 
                                         
Promote monocyte and vascular smooth muscle cell migration into the intima 
and formation of macrophage foam cells. 
2. Incresed production of super oxide anion which will inactivate nitric oxide to 
form peroxynitrite. 
3. Hyperglycemia also causes increased production of lipid second messenger 
diacylglycerol which result in activation of protein kinase c. 
4. There is increased free fatty acid in diabetes mellitus which will impair 
endothelial function. So there will be increased production of very low density 
lipoprotein and cholesteryl ester synthesis and there will be decreased clearance 
by lipoprotein lipase result in hyper triglyceridemia which will lower HDL by 
cholesterol transport from HDL to VLDL. 
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5. Increased production of endothelin 
 
Promote inflammation and causes vascular smooth muscle cell migration and 
proliferation. 
6. Platelet function is also abnormal in diabetes mellitus. 
7. There is increased production of plasma coagulant factors (factor VII and 
Thrombin) and decreased production of anti coagulants such as protein c and 
thrombomodulin. 
Oxidative stress in type 2 DM   
In type 2 DM there is increased oxidative stress resulting in formation of super 
oxide anions. These super oxide anions react with small dense LDL particle 
which undergoes oxidation to form oxidized LDL which is more atherogenic.        
The oxidation of LDL is a complex process during which both the protein and 
the lipids undergo oxidative changes and form complex products. E.g. Non 
enzymatic oxidative changes in amino acids as well as proteolysis and cross 
links of apoprotein B occur that result in extensive alteration in the protein 
composition and structure.  
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The peroxidised lipids decompose generating both free and core aldehyde and 
ketones that covalently modify amino groups of lysine residues of the protein 
moiety. This extensively damaged LDL creates net negative charges that were 
essential for its interaction and uptake by macrophages resulting in formation of 
macrophage foam cells. 
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MANAGEMENT OF HYPERLIPIDEMIA: 
1.NON PHARMACOLOGICAL TREATMENT: 
       Diet control and regular physical activity and weight reduction in 
overweight persons should be aggressively perused. Total caloric intake should 
be decided after giving consideration to the type of work and current weight. 
Fats should provide 25% of the calories and the saturated fats should provide 
7% of the calories. 
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2. Cessation of smoking:  
Smoking and tobacco in any form should be totally avoided. This will help to 
increase HDL cholesterol in those who are tobacco consumers. 
PHARMACOLOGICAL TREATMENT 
All type 2 DM with overt cardiovascular disease and those above 40 years 
without overt cardiovascular disease but having one or more risk factors, should 
be started on statins, irrespective of baseline LDL cholesterol level. In those 
with lesser cardiovascular risk, the first goal is to reduce LDL cholesterol to the 
target goal. If LDL cholesterol levels are >130mg%, pharmacological treatment 
should be started simultaneously with life style measures. If LDL cholesterol is 
between 100-130 mg%, non pharmacological treatment should be started and 
lipids should be repeated after 3 months. If goals are not reached at that time, 
pharmacological treatment should be added. For isolated rise in LDL 
cholesterol, monotheraphy with statins should be preferred. Usually low dose of 
statin are used. However cardiologists use high doses of statins for short periods 
following acute coronary syndrome and coronary angioplasty. Higher doses are 
associated with increased chances of side effects such as hepato toxicity, 
myopathy and occasionally rhabdomyolysis. All the patients should undergo 
LFT and CPK before starting statin therapy. 
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Lipid profiles should be periodically repeated at 3 to 6 monthly interval and 
dosage reduced to half when LDL  goals are reached. 
     Statins also have anti atherosclerotic properties working independently of 
their lipid lowering properties. 
    In patients having contra indications to use of statins or intolerence to statins, 
bile acid sequesterants can also be used. GI disturbances and tendency to raise 
triglycerides level are some of the limitation of these agents. 
The second goal is to increase HDL cholesterol to target level. Non 
pharmacological measures such as cessation of smoking and physical exercise 
should be aggressively perused.Among the pharmacological agents,  best results 
are obtained with nicotinic acid. 
Hypertriglyceredemia: 
     Life style modification and abstinence from alcohol is required. Fibrates are 
the drug of choice if values are more than 400mgs%. 
HYPERTENSION IN DIABETES: 
Hypertension in patients with diabetes is divided in following sub groups. 
1. Surgically curable hypertension(adrenal hypertension) as in cushing's disease, 
primary hyperaldosteronism and pheochromycetoma. In these conditions, both 
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hypertension and diabetes result from hyperfunction of endocrine organ and 
surgical treatment leading to correction of hyperfunction leads to normalization 
of both blood pressure as well as blood glucose. 
Hypertension due to renal artery stenosis can also be treated surgically or by 
non surgical intervention ( renal artery angioplasty). In diabetes, atherosclerosis 
is accelerated and reno vascular hypertension is more common than in general 
population. 
2. Hypertension without diabetic nephropathy 
  a) Isolated systolic hypertension. Systolic BP of 160mm of Hg or more with 
diastolic BP below 90 mm of Hg is more common in diabetes because of 
associated advanced atherosclerosis and resultant loss of arterial elasticity. 
In past isolated systolic hypertension was taken lightly by the medical 
profession due to prevailing belief that it is not as important as elevated diastolic 
blood pressure in pathogenesis of vascular complications. As per the current 
recommendations, isolated systolic hypertension should be as aggressively 
treated as diastolic hypertension  
b) Essential hypertension. This is the commonest type of hypertension in type 2 
diabetic patients. The diagnosis of hypertension may precede, follow or coincide 
with that of diabetes. Its pathogenesis is similar to that of essential hypertension 
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in non diabetics, however additional factors may operate. In recent years the 
role of insulin resistance in genesis of hypertension has evoked considerable 
interest. 
Insulin resistance results in hyperinsulinemia which predisposes to hypertension 
through a variety of mechanism such as 1) increased sympathetic activity, 2) 
increased sodium and water retention, 4) altering sensitivity of vasculature to 
vaso active substances, etc. 
3) Hypertension in those with diabetic nephropathy 
Renal damage in diabetic nephropathy is responsible for hypertension. It is seen 
in pure form in type 1 diabetes with diabetic nephropathy. In middle aged and 
older type 2 diabetics with nephropathy the aetiology of hypertension is often 
mixed. The earliest manifestation of diabetic nephropathy is microalbuminuria. 
At this stage the systemic blood pressure is usually in pre hypertension range 
but intra glomerular pressure is elevated. Administration of ACE inhibitors and 
Angiotensin receptor blockers leads to reduction in intra glomerular pressure 
and reversal micro albuminuria.  
4) Orthostatic hypotension with supine hypertension. When hypertensive 
diabetic develops severe autonomic neuropathy, he develops postural 
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hypertension but he remains hypertensive during the time he is resting in supine 
position.     
Management of hypertension in Diabetes  
Non pharmacological measures should be introduced in pre hypertension stage 
and continued along with pharmacological agents if by themselves, they are not 
sufficient to bring BP down to the target of 130/80 mm of Hg or below. Weight 
reduction in over weight patients by prudent diet control and appropriate 
dynamic exercise (30-40 minutes' walk daily at brisk pace) is very effective and 
proven by non pharmacological measure. It also helps in achieving goal for 
metabolic controls. Hypertensive patients should restrict sodium intake to 5 gm 
per day and refrain from smoking. 
Pharmacological Agents 
If non pharmacological measures do not bring down BP to target, anti 
hypertensive agents should be added. There are certain special considerations 
while selecting an agent in diabetic hypertensive individuals. The agent should 
not worsen metabolic control; it should have beneficial effects on vascular 
complications of diabetes and it should improve the quality of life; and should 
not cause orthostatic hypotension. There is no single agent which fulfils all 
these criteria in all diabetes. One has to study the needs of an individual patient 
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depending upon presence or absence of various vascular complications of 
diabetes and other conditions which could be associated (e.g. COPD/Bronchial 
asthma, CCF), and select appropriate agent. It to be noted that in most of the 
diabetes a combination of two or three anti hypertensive agents representing 
different classes is required to reach target BP. 
Thiazide diuritics 
These are the agents of first choice in stage 1 diabetic hypertensives without 
microalbuminuria. Hydrochlorthiazide in dosage of 12.5 mg daily is safe, 
effective and inexpensive. Its role in preventing vascular complications is 
proved beyond doubt. In the dosage mentioned above, it does not significantly 
increase blood glucose, cholesterol and uric acid levels. If patient has stage 2 
hypertension or if monotherapy with thiazide is not sufficient to reach target BP, 
it can be combined with other agents.  
ACE inhibitors 
These agents are particularly suited for use in diabetic hypertensive patients 
because when given to those who have microalbuminuria, urinary albumin 
excretion can be reverted to nonalbuminuria. These agents can be administered 
even in pre hypertensive diabetic patients with microalbuminuria. At this stage 
intra glomerular pressure is high and its reduction leads to reduction in albumin 
60 
 
excretion rate. Through vasculo protection it offers action beyond blood 
pressure control. In diabetic hypertensive as well as pre hypertensive with 
microalbuminuria ACE inhibitors are the agents of first choice. They can be 
combined with thiazide diuritics if required. Combinations of various ACE 
inhibitors with 12.5mg of hydrochlorthiazide are available. Captopril, Enalapril, 
Lisinopril, Ramipril, Quinalapril and Trandelopril are available in our country. 
Advanced renal failure, hyperkalemia, bilateral renal artery stenosis, pregnancy 
and lactation are contra indications for use of ACE inhibitors. About 10-15% 
patients have to discontinue ACE inhibitors due to intractable cough.  
Angiotensin Receptor blockers (ARBs) 
These agents act on renin angiotensin system, at a step beyond the site of action 
of ACE inhibitors. They also provide reno protective action. Like ACE 
inhibitors, they also have the ability to convert those having micro albuminuria 
to normoalbuminuria. If started in diabetics who already have diabetic 
nephropathy, they slow down the rate of advancement of nephropathy. The time 
taken to reach end stage renal failure as well as double serum creatinine value as 
compared to baseline value at the beginning ofARB therapy is doubled as 
compared to those who do not take ARBs. Losartan was the prototype 
introduced in our country more than a decade back. In a major trial in 
hypertensive patients, Losartan was found to provide vaso protective action. 
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Candensartan, Irbesartan, Olmesartan, Valsartan and Telmesartan are other 
ARBs available in our country. Their indications and contra indications are 
same as those of ACE inhibitors. Their use does not lead to cough; hence they 
can replace ACE inhibitors who develop troublesome cough. Valsarta has been 
found to have beneficial effects in patients suffering from congestive cardiac 
failure. Even though ARBs have action at a site different from that of ACE 
inhibitors on RAAS, and even though both actions are complimentary to each 
other, a large trial on combination of telmisartan and ramipril was unable to 
demonstrate any additional beneficial effects in those on combination therapy. 
("ONTARGET" study). 
Beta blockers, (BB's) 
They are potent anti hypertensive agents and also offer cardio protection. They 
are also indicated for secondary prevention of myocardial infarction. In patients 
with old myocardial infarction and angina pectoris with diabetes, they are 
preferred agents. Non selective beta blockers such as propranalol mask the 
symptoms of hypoglycemia and thus delay diagnosis and treatment. Thus 
selective beta blockers such as Metaprolol or Nebivolol should be preferred. 
Large doses of beta blockers can increase serum cholesterol levels. Thus if a 
moderate dose is insufficient to bring down BP to target, an agent from other 
anti hypertensive group should be added instead of stepping up the dose of beta 
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blockers. Beta blockers are not suitable in patients with associated broncho 
spastic disorders, bradyarrhythmias and several peripheral vascular diseases.   
Calcium channel blockers, (CCBs) 
This anti hypertensive drug class is made up of a few chemically different sub 
classes all sharing anti hypertensive properties but differing in other actions on 
cardio vascular system. (E.g. diltiazem and verapamil reduce heart rate while 
nifidipine tends to increase it). These agents do not have adverse metabolic 
effects, neither are contraindicated in broncho spastic disorders and peripheral 
vascular disease, but at the same time, unlike ACE inhibitors and ARBs, they do 
not offer any special advantage for the treatment of diabetic hypertensive. 
However, in some study, anti atherosclerosis effect and endothelial protection 
have been attributed to amlodipine. Some degree of renal protection is also 
provided by many CCBs. Amlodipine and Felodipine are commonly used 
CCBs. Edema over the feet is the commonest side effect. CCBs can be added to 
any other anti hypertensive agents. Even though usually they are not the agents 
of first choice to start the treatment, CCBs are commonly employed in 
combination with other agents in diabetic patients. 
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ALPHA BLOCKERS 
These agents are metabolically neutral, improve symptoms of prostatism, and 
are not contra indicated in patients having broncho spastic disorders and 
peripheral vascular disease. However postural hypertension is a common side 
effect, which could be troublesome in elderly long standing diabetics having 
autonomic neuropathy.  
Centrally acting agents 
Alpha methyl dopa and clonidine belong to this class of agents. These agents are 
rarely used nowadays due to availability of wide range of agents which are 
better tolerated and equally efficacious. Drowsiness, postural hypertension and 
weakness are some of the common side effects of these agents. Sometimes these 
agents are used in combination with other anti hypertensive agents in diabetics 
with severe hypertension with associated problems making some of the 
commonly used agents unsuitable.  
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Macrovascular complications of diabetes mellitus: 
Coronary artery disease: 
Over 50% of diabetic individuals die due to CAD. Diabetes mellitus and CAD 
share a common soil for the development of the disease. CAD which leads to 
premature myocardial infarction , is the leading cause of death among diabetics 
and results in threefold higher mortality compared to non diabetics. 
RISK FACTORS FOR CAD 
Non modifiable 
 Age 
 Male sex 
 Family history 
Modifiable 
 Cigarette smoking 
 Obesity 
 Diabetes 
 Hypertension 
 Elevated cholesterol 
 Behavioral risk factors 
 
65 
 
Non conventional risk factors; 
       Atherosclerotic/thrombotic risk factors are increased lipoprotein(a), 
homocysteine, plasma fibrinogen, tissue plasminogen, plasminogen activator 
inhibitor-1, c reactive protein. 
Protective factors are exercise,  HDL cholesterol, stress reduction. 
Factors underlying accelerated atherogenesis in diabetes: 
 Insulin resistance 
 Diabetic dyslipidemia 
 Hyperglycemia-glyco oxidation 
 Oxidative stress 
 Hypertension 
 Thrombogenic factors-platelet aggregation,Lp(a),PAI-1, tissue 
plasminogen  activator and fibrinogen 
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TYPE 2 DIABETES MELLITUS PATIENTS WITH ACUTE 
CORONARY SYNDROME: 
       Studies by Mohan et al, Neki et al, Oshima et al, Tseng et al and 
Salehi et al suggest that there is a significant increase is Lp(a) in these 
patients when compared to the non-diabetic group. Since Lp(a) are found 
elevated in type 2 diabetic patients, and as it is associated with increased 
disruption of coronary atherosclerotic plaques,   treatment of Lp(a) and 
associated risk factors may benefit the diabetic patients with acute coronary 
syndrome. 
LIPOPROTEIN(a) LEVEL IN TYPE 2 DIABETE MELLITUS: 
Several studies have revealed that lipoprotein(a) is a independant risk 
factor of coronary artery disease. Lp(a) level is genetically determined. 
Mohan et al, in a community- based study conducted in Chennai, had 
commented on lipoprotein (a) being an important risk factor in type 2 
diabetes mellitus. This study was conducted with diabetic CAD patients, 
diabetic patients without CAD and healthy without coronary artery disease 
and no relationship with glycemic control. While a few other studies 
showed that Lp(a) levels controls. Large population studies and small 
longitudinal studies showed no difference in Lp(a) concentration in type 2 
DM with and are noted to be high in type 2 DM especially with poor 
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glycemic control and some even suggested that Lp(a) may be an independent 
risk factor for CAD. So in type2 diabetes patients with acute coronary 
syndrome lipoprotein(a) level is to be evaluated and it should be treated. 
ACUTE CORONARY SYNDROME: 
Acute coronary syndrome rages fro unstable angina to acute 
myocardial infarction. 
68 
 
ACUTE CORONARY SYNDROME: 
   The clinical presentation of acute coronary syndrome ranges from ST segment 
elevation myocardial infarction, unstable angina to non ST segment elevation 
myocardial infarction. ACS is mainly due to the rupture of atherosclerotic 
plaque and complete or partial thrombosis of the infarct related artery. 
 
 
STEMI occurs, when coronary blood flow stops suddenly by a thrombotic 
occlusion of a coronary artery which is previously affected by atherosclerosis. 
Coronary artery thrombosis develops rapidly at a site of vascular injury, which 
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is facilitated by factors such as hypertension, lipid accumulation and cigarette 
smoking. STEMI occurs due to the disruption of an atherosclerotic plaque. at 
the disrupted site, mural thrombus is formed which occludes the blood flow 
completely results in ST elevation myocardial infarction. 
 
  
After disruption, there is initial platelet aggregation at the site of the disrupted 
plaque by various agonists like collagen, ADP and serotonin. There will be 
activation of thrombaxane -A2, potent vasoconstrictors which causes further 
platelet aggregation. 
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                      The thrombaxane-A2 and various agonists cause changes in            
glycoprotein-IIb/IIIa receptor, which has high affinity for fibrinogen, binds to 
platelets and resulting in platelet cross linking and aggregation.   
At the site of disrupted plaque, coagulation cascade is activated in damaged 
endothelial cells. So factor X and VII are activated leading to conversion of 
prothrombin to thrombin which leads to conversion of fibrinogen to fibrin.  
The damage to myocardium caused by the coronary artery occlusion depends on 
1. The duration of occlusion.  
2. Total or partial occlusion of the artery. 
3. Quantity of blood supplied by the collaterals to the affected myocardial 
tissue. 
4. The demand for oxygen by the myocardium.  
5. Factors that produce spontaneous lysis of occlusive thrombus.  
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6. Adequacy of myocardial reperfusion in the infracted zone. 
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 Unstable angina  
Unstable angina is defined as angina pectoris or equivalent ischemic discomfort 
with at least one of these features. 
1. Angina at rest 
2. New onset angina (with in prior 4-6 weeks) 
3. Pain which is more severe, prolonged or frequent than previous. 
NSTEMI is unstable angina features with elevated cardiac biomarkers. Both 
unstable angina and STEMI are due to reduction in oxygen supply, usually by 
an atherothrombotic coronary plaque. 
The pathological process that associated in the development of unstable 
angina/NSTEMI 
 1. Rupture or erosion of the plaque.  
2. Dynamic obstruction (coronary spasm as seen in prinzmetal's angina) 
3. Rapidly developing coronary atherosclerosis or restenosis following primary 
coronary intervention.  
4. Unstable angina secondary to increased oxygen demand or decreased oxygen 
supply such as anemia/tachycardia. 
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Major goals of treatment: 
-increase coronary artery perfusion 
-decrease myocardial workload 
-prevent myocardial infarction disability or death 
-intervention in cases of unstable angina  
 
  
                         Approach to case of ACS 
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Clinical presentation: 
          Myocardial ischemia or infarction may be silent because of blunted 
appreciation of pain. Most often, the symptoms are atypical such as confusion, 
dyspnoea, fatigue or nausea. These atypical symptoms alter the patient's 
perception of the nature of his or her illness. Autonomic neuropathy in diabetics 
is an ominous sign. The resting tachycardia is due to an unopposed sympathetic 
activity due to parasympathetic denervation. Loss of parasympathetic activity is 
also responsible for exaggerated and inappropriate vasoconstriction. Autonomic 
neuropathy leads to ischemia or infarction by several routes 1) by reduction in 
myocardial blood flow due to increased coronary vascular tone at the sites of 
coronary stenosis 2) increase in resting heart rate leads to increased myocardial 
demand and 3) reducing the coronary perfusion pressure during orthostatic 
hypotension. 
PROGNOSIS: 
           The mortality due to cardiovascular disease is doubled in diabetic men 
and quadrupled in women. Diabetics with symptomatic peripheral vascular 
disease are likely to have significant coronary artery disease though 
asymptomatic. 
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       The prognosis for acute myocardial infarction in a diabetic is rather poor 
compared to anon diabetic. In fact the mortality recorded in coronary care units 
is about 40% compared to 20% in non diabetics. Even when the patients have 
been shifted from critical care unit after coronary care, the mortality is higher in 
diabetic subjects. Hyperglycaemia due to poor metabolic control is a single 
factor related with excess mortality in diabetic myocardial infarcts. The 
prognosis is also influenced by a very high prevalence of cardiogenic shock and 
congestive heart failure complicating acute infarction in diabetic subjects. 
Severe atherosclerosis with impaired coronary collateral circulation, frequent 
association of small vessel disease, microangiopathy and the proneness for 
ketoacidosis possibly contribute to the excess mortality in diabetic subjects.  
MANAGEMENT: 
The management of acute myocardial infarction is similar in diabetics and non 
diabetics subjects expecting that therapy with insulin is mandatory for ensuring 
metabolic control in diabetes for improved outcome. DIGAMI study has proved 
that intensive treatment with insulin glucose infusion targeted to achieve a tight 
control of glycemic level improves survival rate. This intensive treatment was 
also associated with lower one year mortality and morbidity, and the beneficial 
effect was also seen on long term follow up. One has to be cautions in trying to 
achieve a tight glycemic control as this may require a committed teamwork. 
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sThe association of diabetic ketoacidosis with acute myocardial infarction 
enhances the mortality rate to about 85%. Angiography done within the first few 
hours demonstrates total occlusion with thrombosis in about 90% of subjects, 
and intracoronary streptokinase has been found to restore the patency of the 
occluded vessels in two thirds of such subjects. The procedure of angiography 
precipitating acute renal failure due to dehydration in a diabetic subject must be 
kept in mind. In subjects undergoing coronary bypass graft surgery the patency 
of the graft and the post operative morbidity and mortality are similar to the non 
diabetic group. 
THROMBOLYSIS THERAPHY: 
Atypical symptoms in diabetic delay the initiation of thrombolytic therapy. In                           
elderly diabetic patients thrombolytic therapy is associated with high incidence 
of hemorrhagic complication and hence its use is limited to life threatening 
myocardial infarction. Though proliferative retinopathy is a relative 
contraindication for thrombolytic therapy, there have been no recorded 
incidences of retinal hemorrhages in controlled trial studies. Anti thrombotic 
agent abciximab is effective in preventing restenosis in non diabetic subjects 
compared to diabetics. 
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INVASIVE MANEGEMENT: 
Revascularization of the myocardium is considered in patients who have 
ongoing ischemia despite medical therapy. Diabetes needs a large number of 
bypass grafts because of their extensive atherosclerosis. Per operative mortality 
is higher in diabetics due to poor wound healing and associated renal failure. 
Coronary angioplasty is an attractive treatment option because of low associated 
morbidity.    
LIPOPROTEIN (a) MEASUREMENT: 
A standardized international reference material has been developed and is 
accepted by the WHO Expert Committee on Biological Standardization and the 
International Federation of Clinical Chemistry and Laboratory Medicine. 
Lipoprotein(a) - Lp(a) 
 Desirable: < 14 mg/dL (< 35 nmol/l) 
 Borderline risk: 14 - 30 mg/dL (35 - 75 nmol/l) 
 High risk: 31 - 50 mg/dL (75 - 125 nmol/l) 
 Very high risk: > 50 mg/dL (> 125 nmol/l)  
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ELISA METHOD TO MEASURE LIPOPROTEIN(a): 
     
 Among the many technique used to separate lipoprotein, the following 
are important.  
1. Ultracentrifugation  
There are two principle ways of using ultracentrifugation to determine 
lipoproteins. They employ two different instruments, the preparative and 
the analytical centrifuge. 
a) Preparative Ultracentrifugation: Plasma has a salt density of about 
1.006. Ultracentrifugation of plasma without adjustment of its density 
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for a short period brings the chylomicrons rapidly to the top of the 
tube. Longer ultracentrifugation at this density allows the VLDL to be 
collected on the surface. Addition of salt to plasma will further raise 
the density to selected levels and permit isolation of other lipoproteins. 
Those lipoproteins, which are separated below a density of 1.006 
constitute VLDL, 1.006 to 1.063 constitute LDL, 1.063 to 1.21 
constitute HDL.  
b) Analytical Centrifugation: In this instrument, plasma fraction 
usually prepared at salt density of 1.063 is centrifuged at high speeds 
and the moving bands of the floating lipoproteins are photographed 
and later used to determine the concentration that are referred to 
certain standard conditions. 
2. Electrophoresis: 
If the plasma is examined by paper or agarose gel electrophoresis at pH 
8.6, it is possible to demonstrate, by means of fat stains, the existence of 
four bands. Three of these move towards the anode and one remains at the 
origin, that is, the line of application of the serum, the faster moving band 
occurs approximately in the same position as alpha-I globulin. It is known 
as alpha-lipoprotein and corresponds to the HDL fraction, demonstrated 
by ultracentrifugation floatation technique. The next band appears at 
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approximately the position of beta-globulin and is known as beta 
lipoprotein, which corresponds to LDL fraction. Another band appears 
between the position of alpha globulin and beta globulin. It is known as 
pre-beta lipoprotein which corresponds to VLDL fraction. The band, 
which remains stationary at the origin, consists of the chylomicrons. The 
five principal lipoprotein classes are defined according to their density on 
ultracentrifugation and by their mobility on agarose gel electrophoresis. 
In addition, they can be classified on the basis of size and relative 
concentration of cholesterol or triglyceride and by their apoprotein 
content. 
 
METHODS TO REDUCE LIPOPROTEIN(a) LEVEL: 
             At the current time, the recommended treatment for an elevated 
lipoprotein (a) is niacin, 1-3 grams daily, in general in an extended-release form. 
Niacin therapy can reduce lipoprotein (a) levels by 20-30%. Aspirin may be 
beneficial, as well. A recent meta-analysis suggests that atorvastatin may also 
lower Lp(a) levels. In severe cases, such as familial hypercholesterolemia, or 
treatment resistant hypercholesterolemia, lipid aphaeresis may result in dramatic 
reductions of lipoprotein (a). The goal of treatment is to reduce levels to below 
50 mg/dL.  
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Other medications that are in various stages of development include 
thyromimetics, cholesterol-ester-transfer protein (CETP inhibitors), anti-sense 
oligonucleopeptides, and proprotein convertase subtilisin/kexin type 9 (PCSK-
9) inhibitors. L-carnitine may also reduce lipoprotein a levels.  
Gingko biloba may be beneficial, but has not been clinically verified. Co 
enzyme q10 and pine bark extract have been suggested as beneficial, but neither 
has been proven in clinical trials.  
The effect of estrogens on lipoprotein (a) levels is controversial. Estrogens 
replacement therapy in post-menopausal women appears to be associated with 
lower lipoprotein (a) levels. However one large study suggested that there was a 
decreased association between lipoprotein (a) levels and risk. In other words, it 
is unclear what a high lipoprotein (a) level means in a woman on estrogens 
therapy. An estrogen as a prevention strategy for heart disease is current topic of 
much research and debate. Risks and benefits may need to be considered for 
each individual. At present, estrogens is not indicated for treatment of elevated 
lipoprotein(a).  
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                                      METHODOLOGY 
Fifty type 2 diabetic patients and fifty non diabetic patients admitted with acute 
coronary syndrome were selected after matching forage and sex, during the 
study period between july 2014 to September 2014. Lipoprotein(a)was studied 
in these patients. 
                                           SOURCE OF DATA 
    Patients admitted with acute coronary syndrome in cardiac ICU, government 
Rajaji Madurai medical college, Madurai, during the study period of July 2014 
to September 2014. 
                                             SAMPLE SIZE 
                                                  100 cases 
                                      DURATION OF STUDY 
                                    July 2014 to September 2014 
                                       INCLUSION CRITERIA 
Patients with angina, occurring at rest (CCS class IV) of duration more than 30 
minutes, but within 24 hours from onset of angina were included in the study. 
Among them, fifty patients had type 2 diabetes. Fifty age and sex matched non 
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diabetic were included as the other group. Diabetes was ruled out in non 
diabetic group with fasting and 2-hr post prandial blood glucose measurement. 
                                         EXCLUSION CRITERIA 
 Severe hypothyroidism 
 Treatment history of taking oral contraceptive pills. 
 Type1 diabetes 
 Renal failure 
                           METHOD OF COLLECTION OF DATA 
In the present study hundred Acute coronary syndrome patients, who were 
divided in to two separate age and sex matched groups; one with type 2 diabetes 
mellitus and one without Diabetes mellitus, were selected by stratified sampling, 
during the study period as per the inclusion and exclusion criteria. 
   A detailed history (with emphasis on angina/angina equivalent characteristics) 
was taken and a detailed physical examination was done as per the proforma to 
study the clinical profile of patients, blood parameters and imaging as required. 
     All diabetic patients are type 2. Diabetes mellitus was ruled out in non 
diabetic group by fasting and post prandial blood glucose which was analysed 
by GOD-POD (glucose oxidase-phenol 4-aminophenazone peroxidase) method. 
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      10 ml of blood was drawn at the time of admission and lipoprotein(a) 
analyse done by elisa method. Samples were refrigerated till analysis was done. 
Serum lipoprotein (a) level, total cholesterol, LDL, HDL was done. Serum 
Lp(a) was calculated from the Lp(a)-C value by the following formula. 
                                  Lp(a)=Lp(a)-C x 3 
Resting electrocardiogram with 12 standard leads was taken as soon as possible 
and repeated serially and ST segment was monitored. Based on the findings 
both diabetic and non diabetic groups of patients were regrouped. 
1. ST elevation myocardial infarction subgroup 
                     Defined by angina at rest, lasting for more than 30 minutes, in past 
24 hours with 
               a.   ST elevation >2mm (o.2mv) in V1, V2, V3 
                                      Or 
               b. ST elevation >1mm (0.1 mv) inV4, V5, V6  
                                        Or 
               c. ST elevation>1mm (0.1 mV) in two contiguous limb leads 
2. Unstable angina/Non ST elevation myocardial infarction subgroup 
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   Defined by angina at rest, lasting for more than 30 minutes, in past 24 hours 
       a. ST depression >1mm (0.1mV) in two or more contiguous leads 
        b. Inverted T waves >2mm (0.2mV) in leads with predominant R waves. 
 
Other relevant investigations are done 
 ECG in all leads 
 Haemoglobin% 
 Total count 
 Erythrocyte sedimentation rate 
 Blood sugar at the time of admission 
 Fasting and 2 hr blood sugar 
 Blood urea 
 Serum creatinine  
 Serum Lipoprotein (a) 
 Total cholesterol 
 HDL level 
 LDL level 
 Triglycerides 
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 Echocardiogram 
STATISTICAL ANALYSIS: 
      Statistical analysis was done by using percentages, mean values, standard 
deviation, chi-square test, t-test and proportion test. A p-value <0.05 level was 
considered statistically significant and a p-value >0.05 was considered as not 
statistically significant. 
 
 
AGE AND SEX WISE DISTRIBUTION OF CASES: 
 
 
       
 
AGE AND SEX DISTRIBUTION OF CASES 
   
  
DIABETIC 
   
NONDIABETIC 
S.NO  AGE MALE FEMALE TOTAL MALE FEMALE TOTAL 
1 21-30 4 0 4 4 0 4 
2 31-40 7 3 10 4 1 5 
3 41-50 4 5 9 5 7 12 
4 51-60 4 12 16 7 6 13 
5 61-70 3 5 8 1 9 10 
6 71-80 2 0 2 2 2 4 
7 81-90 1 0 1 2 0 2 
  
25 25 50 25 25 50 
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The following observations are made from above chart 
a. Majority of students belongs to the age group of 51-60 years of age. 
b. There is no significant difference in age wise distribution of cases in both 
groups, so they are comparable p<0.05 
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SEX WISE DISTRIBUTION OF CASES IN DIABETIC AND NON 
DIABETIC:  
In the above pie diagram shows that both in diabetic and non diabetic female 
groups, the incidence of disease is more common in the age groups of 51-60 
years of female patients. 
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SEX WISE DISTRIUTION OF CASES IN DIABETIC AND NON 
DIABETICS WITH ACS; 
In the above pie diagram it shows that in both diabetic and non diabetics male 
patients the incidence of disease is more common in age group of 51-60 years of 
male patients. 
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AGE WISE DISTRIBUTION OF LIPOPROTEIN (a) LEVEL IN 
DIABETIC GROUP: 
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AGE WISE DISTRIBUTION OF Lp(a) IN DIABETIC GROUPS 
  S.NO LP(a) levels 
 
AGE IN YEARS 
   
  
21-30 31-40 41-50 51-60 61-70 >71 
1 0-15 1 2 1 4 2 1 
2 16-30 1 6 2 7 4 1 
3 31-45 2 2 3 4 1 1 
4 46-60 0 0 3 2 0 0 
 
TOTAL 4 10 9 17 7 3 
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The following observations was made from above chart  
a. The maximum value of   Lp (a) level seen in 51-60 age group. 
b. The minimum value of   Lp (a) level seen in 21-30 age group. 
c. 90% of diabetic patients have Lp (a) levels more than 15mg/dl. 
d. 32% of diabetic patients have Lp(a) level more than 30 mg/dl. 
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AGE WISE DISTRIBUTION OF Lp(a) IN NON-DIABETIC GROUPS: 
        
 
AGE WISE DISTRIBUTION OF Lp(a) IN NON DIABETIC 
GROUPS 
  S.NO Lp(a)Levels 
 
AGE IN YEARS 
   
  
21-30 31-40 41-50 51-60 61-70 >71 
1 0-15 2 5 9 12 9 6 
2 16-30 2 0 3 1 1 0 
3 31-45 0 0 0 0 0 0 
4 46-60 0 0 0 0 0 0 
 
TOTAL 4 5 12 13 10 6 
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The following observation was made from above chart 
A. Most of the non diabetic group patients have Lp (a) level of less than 
15mg/dl. 
B. Only 10% of non diabetic group have value more than 15mg/dl. 
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COMPARISON OF Lp(a) LEVEL INDIABETIC AND NON DIABETIC 
GROUP: 
   
 Comparing Lp(a) level in diabetic and non diabetic group 
GROUP                    MEAN (S.D) (mg/dl) 
Type 2 Diabetic -    27.62±12.5 
Non diabetic      - 12.5±5.42 
   Difference between means of serum Lp(a) level in both groups is 
significant(p<0.001).Type 2 diabetic patients had a higher Lp(a) levels 
compared to non diabetics with acute coronary syndrome. 
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COMPARISON OF LDL LEVEL IN DIABETIC AND NON DIABETIC 
GROUP 
 
GROUP                     MEAN (S.D) 
DIABETIC                114±19.8 
NON DIABETIC       101.2±11.63 
Serum LDL  levels are significantly higher in diabetic group when compared to 
non diabetic group (p<0.0001). 
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Comparison of total cholesterol in both diabetic and non diabetic group 
with ACS: 
 
The following observation was made from the above chart: 
Serum levels of total cholesterol in diabetics are significantly high when 
compared to non diabetics with acute coronary syndrome (p<0.001). 
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Comparison of Triglycerides Level in diabetic and non diabetic with ACS: 
 
The following observation was made from above chart: 
Serum Triglycerides level is significantly higher in diabetics when compared to 
non diabetics (p <0.001) with acute coronary syndrome. 
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Comparison of HDL Cholesterol level in diabetic and non diabetic with 
ACS: 
 
The following observation was made from above chart 
Serum HDL levels was significantly lower in diabetic group when compared to 
non diabetic group with ACS (p<0.001). 
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COMPARING Lp(a) LEVEL AND LIPID PROFILE IN BOTH GROUP 
WITH ACUTE CORONARY SYNDROME: 
     S.NO PROFILE DIABETICS NON DIABETICS p VALUE 
1 LDL 114±19.79 101.2±11.65 <0.001 
2 TOTALCHOLESTEROL 188.4±26.15 161±21.13 <0.001 
3 TRIGLYCERIDES 193.72±34.39 140±16.37 <0.001 
4 HDL LEVEL 29.02±10.42 48.3±11.20 <0.001 
5 Lp(a) LEVEL 27.62±12.80 12.5±5.42 <0.001 
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Serum Lp(a) level, Total cholesterol, Triglycerides, LDL were significantly 
higher in type 2 diabetic group when compared to non diabetic 
group(p<0.001).HDL level was significantly lower in type 2 diabetic group than 
non diabetic group(p<0.001). 
Number of cases having significantly high Lp(a) level and odds ratio for 
diabetic group  
 Number of case                Lp(a) >15mg/dl     Lp(a)<15mg/dl   
DIABETIC GROUP              39                           11 
NONDIABETIC GROUP      7                             43 
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ODDS RATIO                        21.77 
                     95%CL   7.6822 to 61.7449 
                    z statistic   5.795 
                       p value   <0.0001 
RELATIVE RISK                    4.16 
                             95%CL    2.4221 TO 7.1519 
                   Z STATISTIC    5.163 
                             p value    <0.0001 
Diabetic group had an odds ratio of   21.7 when compared to non diabetic 
group, in having Lp(a) levels >15mg/dl. There is a positive correlation of serum 
LP(a) levels with LDL and  triglycerides level.                     
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DISCUSSION  
     In Asian Indians, the coronary artery disease rate has been raised rapidly. 
The cause for its high prevalence of coronary artery disease in Asian Indians has 
been largely unexplained. It is due to the failure of traditional risk factors to 
explain which raises the possibility of a genetic susceptibility to coronary 
disease in Asian Indians.       
   So, studies on lipoprotein(a) levels are significant as lipoprotein(a) is known 
to be genetically determined. As Lp(a) values are different in various ethnic 
group populations, but in most of the studies revealed that south Asians have 
higher level of Lp(a) concentrations. It is proved by Enas et al study. Similar to 
this, the present study also showed that Lp(a) levels are increased in  our 
population.  
      In diabetes mellitus, 67% of deaths are due to coronary artery disease. 
Framingham heart study showed that CAD, acute myocardial infarction and 
sudden death is 1-5 fold increased in diabetes patients. So, diabetic patients with 
coronary artery disease have worst prognosis when compared to non diabetic 
patient with CAD. Diabetes also predisposes to early thrombus, smooth muscle 
proliferation, endothelial and platelet dysfunction.          
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         In the present study, hundred patients with acute coronary syndrome were 
taken, of which 50 patients are diabetic and 50 patients non diabetic. Serum 
Lp(a) was compared between these two groups, along with comparison of other 
parameters.   
      The two groups were selected from cases of acute coronary syndrome 
admitted at cardiology department of government Rajaji hospital, Madurai 
medical college, between July 2014 and September 2014. Both groups have 
equal number of cases and were age and sex matched for uniform comparison. 
comparison of clinical profile in various studies 
   STUDY           NO        AGE        MALE/FEMALE   PROPORTION 
Mohan et al 100 54 ± 8.1           72/28 1 
 
Gazzarusso et 
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56.6± 2.3         62/13 
 
1.1
2  
 
Tseng et al 
 
 
556 
 
 
63. ± 10.4      43.6/56.4 
 
 
1.0
2  
Salehi et al 
 
115 
 
58.7± 13          31/10 
 
1.2 
Present study     100      50.82±13          50/50          1 
 The mean age of the cases studied in the present study is 
comparatively younger (p>0.05) than similar studies, except Mohan et al,  
with which the age is comparable. Ariyo et al in the suggest that elevated 
levels of lipoprotein (a) independently predict an increased risk of stroke, 
death from vascular disease, and death from all causes, in men but not in 
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women above the age of 60 years. Since the mean age in the present study 
is below 60, influence of increased age does not confound the results. 
 
In the present study the mean age is in the early fifth decade, which is 
comparable to Mohan et al. This may be due to occurrence of acute coronary 
syndrome in an earlier age in the South Indian patients compared to western 
population. 
The ratio between male and female patients in both controls and cases 
were proportionate in all the studies.   Gender bias is also removed as both 
the groups are matched. 
Post-menopausal state influences serum Lp(a) levels. Both the diabetic 
and non- diabetic group had comparable fraction of such  patients.  Females   
on Hormone replacement therapy were also excluded from the study as it 
alters athero thrombotic risk and Lp(a) levels. 
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Comparison of Lp(a) level in type -2 diabetics and non diabetics in 
various studies 
Author No. of cases Lp(a) level in 
diabetes 
Lp(a) level in 
non diabetes 
Mohan et al 100 15.1±3.3 12.1±4.6 
Tseng et al 557 18.1±15.5 14.9±5.9 
Neki et al 134 14.9±3.5 11.9±4.1 
Salehi et al 115 16.8±4.4 13.3±5.1 
Present study 100 27.62±12.8 12.5±5.42 
              In the present study, Lp(a) values varied from 7 to 60mg/dl. Type-2 
diabetic patients had higher Lp(a) level compared to non diabetic patients. 
The difference of means was statistically significant (p<0.0001). This was 
comparable with Mohan et al, Neki et al, and Salehi et al. This was because 
of similar patient sample and method used to measure serum Lp(a) level.  
        In the present study, considering the optimal cut off points at 15mg/dl, 
80% of type-2 diabetic patients had Lp(a) > 15mg/dl, compared to 20% of 
non diabetic patients.  
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       Type-2diabetic patients, have nearly 2 fold risk of higher serum 
lipoprotein(a) compared to non diabetic group, during acute coronary 
syndromes.  
       This phenomenon may be explained by 2 hypotheses: 
A) Diabetic group had a pre existing high base line serum Lp(a) which 
contributed to the pre mature acute coronary syndromes. 
B) Diabetic group underwent an accelerated acute phase reaction to acute 
coronary syndrome and may be prognostic marker in such situations. 
Lp(a) level and lipid profile 
   In the present study, serum total cholesterol, LDL level, triglycerides and 
Lp(a) level were significantly higher(p<0.0001) in the diabetic group when 
compared to non diabetic groups. 
       HDL are significantly lower in diabetic group when compared to non 
diabetic groups. In the present study, there was moderate positive correlation 
between serum Lp(a) levels and serum total cholesterol and LDL. This was 
consistent with Mohan et al. Raised Lp(a) can increase the coronary artery 
disease risk along with raised LDL in type-2 diabetes. 
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       This suggests the basis for a genetic pre disposition to coronary artery 
disease among populations with elevated Lp(a) levels and concomitantly 
raised LDL levels. 
MORBIDITY AND MORTALITY: 
Diabetic patients with acute myocardial infarction have a higher 
mortality. Since the present study had a small sample and is a cross sectional 
study, this result cannot be concluded. 
In the present study, cardiac arrest occurred in two diabetic patients 
because of fatal secondary ventricular fibrillation.  Cardiac arrest occurred  
in  one  non-diabetic patient, who survived a sustained pulseless ventricular 
tachycardia.According to McGuire et al, during acute coronary syndrome, 
type 2 diabetes  independently predicted mortality (relative risk [RR], 1.57), 
as well as cardiovascular death, new myocardial infarction, stroke, and new 
congestive heart failure. Moreover, compared with their non-diabetic 
counterparts, women had a significantly higher risk than men (RR, 1.98 
and RR, 1.28). Interestingly, diabetic patients without prior cardiovascular 
disease had the same event rates for all outcomes as non-diabetic patients 
with previous vascular disease.    
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                               CONCLUSION 
          Type-2 diabetic patients have higher level of Lp(a) level during acute 
coronary syndrome when compared to non diabetic group. So, the type-2 
diabetic patients have nearly 2 fold risk of having high Lp(a) level than non 
diabetic group. 
      Elevated Lp(a) in type -2 diabetic patients contribute to the accelerated 
atherogenic / prothrombotic state, causing major adverse cardiac events. 
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                                        SUMMARY 
 Serum Lp(a) level is high in type -2 diabetic patients with acute 
coronary syndrome when compared to non diabetic patients. 
 Mean serum Lp(a) in present study was 27.62±12.8mg/dl. The value 
of Lp(a) varies from 7mg/dl to 60mg/dl. 
 Triglycerides, total cholesterol and LDL were significantly higher in 
patients with type -2 diabetics and acute coronary syndrome compared 
to non diabetic patients. 
 HDL cholesterol levels were significantly lower in patients with type -
2 diabetic patients when compared to non diabetic group with acute 
coronary syndrome.   
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MASTER CHART 
DIABETIC PATIENTS: 
S.NO NAME AGE SEX LDL TC TG HDL Lp(a) 
1 VIJAYA 48 F 124 217 270 14 60 
2 SANKAR 45 M 112 190 192 35 40 
3 KARUPAYEE 51 F 125 214 214 20 55 
4 ALAGU 63 M 96 162 145 44 10 
5 RAJENDRAN 37 M 119 182 194 35 42 
6 RASATHY 56 F 120 172 198 35 35 
7 INDIRANI 49 F 124 174 207 15 38 
8 ALAGUMATHY 60 F 121 185 209 18 35 
9 VEERAN 58 M 106 182 191 20 28 
10 ABDULLA 38 M 62 172 146 40 10 
11 RAJASEKARAN 54 M 119 174 188 30 25 
12 RAJALAKSHMI 68 F 115 185 187 35 25 
13 PALANIAPPAN 66 M 118 182 192 44 28 
14 VIJAYAKUMAR 35 M 109 173 201 40 18 
15 SURESH 31 M 107 172 200 38 15 
16 POTHUMPONNU 66 F 121 206 218 20 35 
17 NATARAJAN 61 M 101 191 198 30 20 
18 BALAJI 28 M 123 172 228 14 40 
19 GANESH 39 M 121 207 229 15 40 
20 IRULLAYEE 55 F 124 203 225 18 38 
21 KARUPPASAMY 55 M 129 205 226 18 32 
22 ANNAMALAI 52 M 125 204 221 17 50 
23 LAKSHMI 56 F 91 161 144 42 12 
24 SELVI 54 F 105 164 167 32 15 
25 RAJANGAM 81 M 109 172 175 35 12 
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MASTER CHART FOR DIABETIC PATIENTS CONTINUES.. 
26 RAJATHI 61 F 122 216 219 30 7 
27 RAGHURAM 53 F 99 164 146 40 10 
28 KANNIYAMMAL 58 F 111 172 181 32 20 
29 KAVITHA 35 F 113 171 186 34 25 
30 SUNDARAM 49 M 119 178 190 30 14 
31 RAJA 34 M 126 225 224 25 30 
32 MEENAKSHI 52 F 120 189 260 18 26 
33 VINOTHKUMAR 30 M 97 164 146 30 14 
34 ASHARUDEEN 26 M 100 175 158 36 20 
35 VIJAYAVEERAN 47 M 123 270 280 15 55 
36 VEERAYEE 46 F 206 164 148 44 50 
37 VANITHA 44 F 124 206 224 15 35 
38 LAKSHMI 62 F 120 208 209 17 30 
39 KANNABIRAN 48 M 130 165 146 40 20 
40 ARAYEE 60 F 106 171 168 38 15 
41 LAKSHMI 68 F 109 172 171 35 20 
42 SURENDIRAN 36 M 128 270 250 20 20 
43 SUNDARAMOORTHY 75 M 127 250 218 20 24 
44 ANANTHI 40 F 96 163 150 44 25 
45 BALASARASWATHI 57 F 60 164 154 20 22 
46 SIVAKUMAR 28 M 108 184 171 35 33 
47 MATHIYAZHAGAN 78 M 102 186 170 28 35 
48 SUNDARI 38 F 118 193 181 25 28 
49 MARIAMMAL 50 F 121 217 220 21 25 
50 MARUTHAYEE 60 F 98 162 151 55 20 
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MASTER CHART : 
 
NON DIABETC PATIENTS 
S.NO NAME AGE SEX LDL TC TG HDL Lp(a) 
1 CHELLAPPAN 74 M 94 141 119 60 10 
2 SIVAKUMAR 40 M 95 144 120 62 11 
3 SENNIYAMMAL 65 F 101 154 135 50 7 
4 BALAMURUGAN 56 M 102 156 143 50 12 
5 LAKSHMIYAMMAL 65 F 111 162 155 52 10 
6 KALLIAYAMMAL 80 F 96 141 121 58 14 
7 KALASALINGAM 58 M 97 150 128 48 15 
8 KARUPPANNAN 60 M 114 161 155 46 10 
9 IRULLAYEE 60 F 116 162 161 45 10 
10 SHANMUGAM 81 M 118 160 180 19 10 
1 SELVI 45 F 96 145 121 58 7 
12 MARUTHAYEE 68 F 95 143 125 55 7 
13 VIJAY 29 M 94 144 127 54 10 
14 GOPAL 45 M 95 149 131 54 6 
15 THANGALAKSHMI 66 F 99 151 138 50 12 
16 SHAHUL HAMEED 28 M 96 151 134 60 15 
17 INDRANI 72 F 102 158 144 48 14 
18 MALAR 58 F 103 168 148 48 20 
19 POOVAYEE 61 F 110 167 147 45 14 
20 NACHIYAPPAN 78 M 111 161 150 25 14 
21 PARAMESHWARAN 50 M 93 141 124 60 10 
22 SELVAM 44 M 80 144 125 62 11 
23 KUMARI 67 F 114 165 140 55 12 
24 JOTHI 45 F 118 190 160 25 25 
25 SRINIVASAN 62 M 116 174 155 30 18 
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MASTER CHART FOR NON DIABETIC PATIENT CONT.. 
 
26 PREMKUMAR 34 M 110 168 151 48 15 
27 VEERALAKSHMI 48 F 94 141 119 58 12 
28 RAJAN 88 M 74 144 121 54 10 
29 ANAND 40 M 102 190 145 48 10 
30 BHARATHI 50 F 114 158 154 46 11 
31 KANNAN 48 M 110 155 179 35 6 
32 ARUNACHALAM 40 M 94 145 120 55 13 
33 INDIRA 54 F 99 148 132 55 14 
34 KALAIVANI 40 F 99 156 145 44 14 
35 GOVINDAMMAL 44 F 125 250 156 42 30 
36 PARAMESHWARI 63 F 80 146 127 58 7 
37 SEETHAPATHI 56 M 95 144 128 55 10 
38 VALLI 58 F 101 160 147 35 10 
39 NIRMALA 48 F 76 200 122 58 7 
40 KANNIYAMMAL 62 F 104 166 135 45 6 
41 JOTHILAKSHMI 49 F 96 190 120 62 10 
42 RAJATHI 52 F 116 210 140 20 10 
43 
BALA 
SUBRAMANI 55 M 105 164 155 45 5 
44 KAYALVIZHI 47 F 104 168 156 50 20 
45 GANESAN 53 M 75 146 170 60 10 
46 RAJKUMAR 29 M 98 148 128 54 25 
47 SARAVANAN 29 M 94 151 124 54 20 
48 KARUPPAYEE 60 F 108 175 135 50 11 
49 NATARAJAN 55 M 104 166 156 40 10 
50 ANJUGAM 62 F 117 200 162 25 25 
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                                 PROFORMA 
 
Comparative study of lipoprotein (a) level in diabetics and non-diabetics 
with acute coronary syndrome         
 
NAME:                                                                                                  CASE NO: 
AGE/SEX:                                                                                             IP NO       : 
OCCUPATION:                                                                                   DOA          : 
ADDRESS:                                                                                           DOD          : 
 
 
HISTORY OF PRESENTING COMPLAINTS: 
1. H/O Chest pain 
Duration: 
           Associated with sweating ,palpitation, dizziness: YES/NO 
           Aggravating factors: 
            Relived by rest: YES/NO 
2. H/o dyspnoea: 
           NYHA Class: 
           H/o orthopnoea present or not: 
3.H/o cough- 
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PAST HISTORY: 
H/o diabetes mellitus:  yes/no 
    If yes, duration:                                     
Anti-diabetic drugs: 
H/o hypertension: 
H/o CVA: 
H/o PTB: 
H/o epilepsy: 
PERSONAL HISTORY: 
 
FAMILY HISTORY: 
 
EXAMINATION: 
GENERALEXAMINATION: 
 
VITALS: 
Pulse:                                       Blood pressure:                                  RR:                     spo2: 
 
ANTHROPOMETRY: 
 Height:                                     Weight:                              BMI: 
 Pallor 
 Cyanosis 
Clubbing 
 Generalized lymphadenopathy 
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 RESPIRATORY SYSTEM: 
 
 ABDOMEN EXAMINATION: 
 
CNS EXAMINATION: 
 
 
INVESTIGATIONS: 
Blood sugar at the time of admission: 
 
Fasting blood sugar:                           2hr blood sugar: 
 
Blood urea:                                          serum creatinine: 
 
Hb:                                                       urine analysis: 
 
LIPID PROFILE: 
           Total cholesterol: 
           TGL level          : 
           HDL level          : 
           LDL level          : 
           VLDL level       : 
          LIPOPROTEIN(a) level: 
 
Echocardiogram: 
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THYROID PROFILE: 
 
ELECTROCARDIOGRAM: 
 
ECG AT THE DAY  
OF 
ADMISSION 
 
1
ST
 DAY 2
ND
 DAY 3
RD
 DAY 
RATE     
RHYTHM     
AXIS     
P WAVE     
PR 
INTERVAL 
    
Q WAVE     
QRS     
ST SEGMENT     
T WAVE     
QTC 
INTERVAL 
    
 
TREATMENT: 
 
FOLLOW UP:  
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